WO2002009749A3 - Respiratory syncytial virus vaccine - Google Patents

Respiratory syncytial virus vaccine Download PDF

Info

Publication number
WO2002009749A3
WO2002009749A3 PCT/CA2001/001104 CA0101104W WO0209749A3 WO 2002009749 A3 WO2002009749 A3 WO 2002009749A3 CA 0101104 W CA0101104 W CA 0101104W WO 0209749 A3 WO0209749 A3 WO 0209749A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
protein
respiratory syncytial
syncytial virus
immunogenic
Prior art date
Application number
PCT/CA2001/001104
Other languages
French (fr)
Other versions
WO2002009749A2 (en
Inventor
Mark Parrington
Robert J Sloan
Valerie Sales
Judith Atkins
Ernst Braendli
Mathilde Luciani
Bernard Cornet
Bruce Carpik
Original Assignee
Aventis Pasteur
Mark Parrington
Robert J Sloan
Valerie Sales
Judith Atkins
Ernst Braendli
Mathilde Luciani
Bernard Cornet
Bruce Carpik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Mark Parrington, Robert J Sloan, Valerie Sales, Judith Atkins, Ernst Braendli, Mathilde Luciani, Bernard Cornet, Bruce Carpik filed Critical Aventis Pasteur
Priority to CA002417274A priority Critical patent/CA2417274A1/en
Priority to AU2001278337A priority patent/AU2001278337A1/en
Priority to US10/333,839 priority patent/US20040022800A1/en
Priority to EP01956244A priority patent/EP1305043A2/en
Publication of WO2002009749A2 publication Critical patent/WO2002009749A2/en
Publication of WO2002009749A3 publication Critical patent/WO2002009749A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

An immunogenic composition which may be formulated for protection of a host against disease caused by infection by Respiratory Syncytial Virus (RSV) is provided. The immunogenic preparation comprises at least one protein of RSV or at least one immunogenic fragment of the at least one protein and is not adjuvanted. The at least one RSV protein may be the F, G or M protein from a RSV A or RSV B strain. The compositions may be stabilized for storage. Methods of immunization using the immunogenic preparations are also provided.
PCT/CA2001/001104 2000-07-31 2001-07-31 Respiratory syncytial virus vaccine WO2002009749A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002417274A CA2417274A1 (en) 2000-07-31 2001-07-31 Respiratory syncytial virus vaccines
AU2001278337A AU2001278337A1 (en) 2000-07-31 2001-07-31 Respiratory syncytial virus vaccine
US10/333,839 US20040022800A1 (en) 2000-07-31 2001-07-31 Respiratory syncytial virus vaccine
EP01956244A EP1305043A2 (en) 2000-07-31 2001-07-31 Respiratory syncytial virus vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170600P 2000-07-31 2000-07-31
US60/221,706 2000-07-31

Publications (2)

Publication Number Publication Date
WO2002009749A2 WO2002009749A2 (en) 2002-02-07
WO2002009749A3 true WO2002009749A3 (en) 2002-04-18

Family

ID=22828986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001104 WO2002009749A2 (en) 2000-07-31 2001-07-31 Respiratory syncytial virus vaccine

Country Status (5)

Country Link
US (1) US20040022800A1 (en)
EP (1) EP1305043A2 (en)
AU (1) AU2001278337A1 (en)
CA (1) CA2417274A1 (en)
WO (1) WO2002009749A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
EP1713824A2 (en) * 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
EP1701738B1 (en) 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
EP2089515A4 (en) * 2006-11-16 2011-02-23 Novavax Inc Respiratory syncytial virus-virus like particle (vlps)
CL2007002710A1 (en) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Immunogenic formulation that confers protection against infection or pathology caused by the respiratory syncytial virus (vrs) comprising an attenuated recombinant strain of mycobacterium; and use of the immunogenic formulation to prepare a vaccine to prevent, treat or attenuate infections of vrs.
BRPI0915696B8 (en) * 2008-11-07 2021-05-25 Serum Institute Of India Ltd lyophilized rotavirus vaccine composition and method of preparing said composition
CN102762226A (en) 2009-06-10 2012-10-31 诺华有限公司 Benzonaphthyridine-containing vaccines
CN102294027A (en) * 2011-07-26 2011-12-28 昆明理工大学 Respiratory syncytial virus F2 protein subunit vaccine and preparation method thereof
CN103145590B (en) * 2013-03-06 2014-05-28 山东阜丰发酵有限公司 Clean L-arginine production technology
RU2746280C1 (en) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Respiratory syncytial virus strain rsv/novosibirsk/66h1/2018 for use in the diagnosis of respiratory syncytial viral infection and the study of the effectiveness of antiviral drugs in vitro

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
WO1987004185A1 (en) * 1986-01-14 1987-07-16 University Of North Carolina Vaccines for human respiratory virus
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
WO1998002457A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
WO1999062500A1 (en) * 1998-06-03 1999-12-09 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO2000035481A2 (en) * 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
WO1987004185A1 (en) * 1986-01-14 1987-07-16 University Of North Carolina Vaccines for human respiratory virus
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
WO1998002457A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
WO1999062500A1 (en) * 1998-06-03 1999-12-09 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO2000035481A2 (en) * 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAMS, GERALD D. J.: "Lyophilization of vaccines", VACCINE PROTOC. (1996), 167-185. EDITOR(S): ROBINSON, ANDREW;FARRAR, GRAHAM H.; WIBLIN, CHRISTOPHER N. PUBLISHER: HUMANA, TOTOWA, N. J., - 1996, XP001053472 *
GUPTA C K ET AL: "Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 15, 1 October 1996 (1996-10-01), pages 1417 - 1420, XP004070953, ISSN: 0264-410X *

Also Published As

Publication number Publication date
CA2417274A1 (en) 2002-02-07
AU2001278337A1 (en) 2002-02-13
US20040022800A1 (en) 2004-02-05
WO2002009749A2 (en) 2002-02-07
EP1305043A2 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
WO2002013857A8 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
IL174413A0 (en) Immunological adjuvants compounds
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
BR9712970A (en) Method for producing vaccine for protection against respiratory syncytial virus, mixture of purified fusion protein, immunogenic composition
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
WO2003061555A3 (en) West nile vaccine
WO2003024354A3 (en) Interleukin-12 as a veterinary vaccine adjuvant
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2002009749A3 (en) Respiratory syncytial virus vaccine
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2000035481A3 (en) Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
WO2006114312A3 (en) Vaccine
WO2002009752A3 (en) Immunological adjuvant compounds
WO2001022994A3 (en) Vaccines against neisseria infection
WO2001005424A3 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
WO2003022878A3 (en) Subunit respiratory syncytial virus vaccine preparation
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2002096940A3 (en) Attenuated very virulent infectious bursal disease virus
WO2003094962A3 (en) Ebv vaccine using gp350 antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2417274

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001956244

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001956244

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10333839

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP